Based on emerging links between αSyn pathology and lipid biology, which includes the demonstrated evidence for SCD inhibition in mitigating αSyn pathologies, a medicinal chemistry campaign was initiated to identify brain-penetrant SCD inhibitors as therapeutics for synucleinopathies. The gene discussed is SCD; the disease is synucleinopathy.